Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023 16:29 ET
|
Olema Oncology
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
November 28, 2023 17:10 ET
|
Olema Oncology
Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with...
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023 16:02 ET
|
Olema Oncology
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarterNew clinical data for palazestrant...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2023 16:32 ET
|
Olema Oncology
SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Participate in Upcoming Investor Conferences in November
November 01, 2023 16:27 ET
|
Olema Oncology
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
October 22, 2023 02:55 ET
|
Olema Oncology
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis...
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
October 17, 2023 07:01 ET
|
Olema Oncology
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
October 16, 2023 07:02 ET
|
Olema Oncology
Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23,...
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
October 12, 2023 07:01 ET
|
Olema Oncology
SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
October 10, 2023 07:00 ET
|
Olema Oncology
Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded study supports the potential...